Plain-English translation of NCT05113537 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether , a drug that blocks certain cancer growth proteins, can prepare your cancer cells to be more responsive to a targeted radiation treatment called 177Lu-PSMA-617. The idea is that the medication works as a "primer" โ it makes cancer cells light up more brightly on imaging scans and become more vulnerable to the radiation therapy that follows.
Advanced prostate cancer that has become resistant to hormone therapy is difficult to treat, and many patients run out of effective options. This trial is exploring whether combining this medication with radiation therapy might help patients live longer and control their disease better.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
In Part A (the first phase), you would take the medication by mouth for 14 days, then receive the radiation treatment as an infusion on day 15. The full cycle repeats every 6 weeks for up to 4 cycles, depending on how well you respond and whether side effects occur. You will have regular imaging scans, blood tests, and clinic visits to monitor how the treatment is working and to check for any side effects.
AI-generated summary from trial data ยท Aug 12, 2026 ยท Not medical advice
United States